Company profile for Gyre Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various...
Gyre Therapeutics, based in San Diego, CA, is a biopharmaceutical company with a primary focus on developing and bringing to market Hydronidone (F351) for treating Metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Formerly known as Nonalcoholic Steatohepatitis (NASH), MASH fibrosis is the target condition for Hydronidone, currently under evaluation for the treatment of liver fibrosis in various chronic liver diseases in the United States. The drug is being assessed under an active Investigational New Drug (IND) application.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12770 High Bluff Drive, Suite 150 San Diego, CA 92130
Telephone
Telephone
+1 8585677770
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/07/3183482/0/en/Gyre-Therapeutics-Reports-Third-Quarter-2025-and-Year-to-Date-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3166931/0/en/Gyre-Therapeutics-Announces-Completion-of-Patient-Enrollment-in-Phase-3-Clinical-Trial-of-Pirfenidone-Capsules-for-the-Treatment-of-Pneumoconiosis.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/10/14/3166004/0/en/Gyre-Therapeutics-to-Present-Results-from-Positive-Phase-3-Clinical-Trial-Evaluating-Hydronidone-for-the-Treatment-of-Liver-Fibrosis-in-Chronic-Hepatitis-B-at-AASLD-The-Liver-Meeti.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/09/05/3145489/0/en/Gyre-Therapeutics-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
05 Sep 2025

https://www.globenewswire.com/news-release/2025/08/22/3137760/0/en/Gyre-Therapeutics-Announces-the-Appointment-of-Dan-Weng-M-D-to-Board-of-Directors.html

GLOBENEWSWIRE
22 Aug 2025

https://www.globenewswire.com/news-release/2025/08/11/3131212/0/en/Gyre-Therapeutics-Reports-Second-Quarter-2025-and-Year-to-Date-Financial-Results-and-Provides-Business-and-Leadership-Update.html

GLOBENEWSWIRE
11 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty